AC Immune acquires Parkinson’s disease vaccine candidate
AC Immune is set to acquire Affiris’ entire portfolio of therapeutics targeting alpha-synuclein
Read More
Tag: Affiris
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
